Mednet Logo
HomeRadiation OncologyQuestion

How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?

5
4 Answers
Mednet Member
Mednet Member
Radiation Oncology · UCLA | VA Greater Los Angeles Healthcare System

If a patient has already received 3-4 months of a platinum-doublet chemotherapy during the chemo-immunotherapy phase, then it's always my preference to omit further chemotherapy and recommend RT alone. The rationale for this recommendation is that we don't administer additional chemotherapy to patie...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · City of Hope

I still try for 60 Gy in 15 fractions if radiation alone, though I will dose adjust based on my OARs and at times underdose the PTV to maybe 52.5 Gy and try for 60 Gy to the ITV.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Loma Linda University

After a full course of neoadjuvant chemo‑immunotherapy, I would be cautious about increasing BED when treating locally advanced NSCLC with RT alone. Several observations from prior trials favor this approach.

In RTOG 0617, dose intensification did not improve outcomes and was associated with worse s...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Mallory Radiotherapy, PLLC

I would base this decision on the extent of central disease and PTV overlap of the esophagus, favoring conventional fractionation in these cases (I would try for at least 66 Gy in 33 treatments with RT alone). The bulk of residual disease and history of pneumonitis would also be a factor, as you are...

Register or Sign In to see full answer